Anbio Biotechnology (NNNN) stock
NNNNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 7, 2026Score 11/30
$3.32−0.33 (-9.04%)
Close on Nov 20, 2026Market cap $477.72MP/E 22.6Yield –
Anbio Biotechnology operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2025 it was $5.77M, up 189.1% from the year before.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.77M | +189.1% |
| FY2024 | Dec 31, 2024 | $2.00M | +1.8% |
| FY2023 | Dec 31, 2023 | $1.96M | -80.8% |
| FY2022 | Dec 31, 2022 | $10.20M | – |
See a number that looks wrong?